← All trials
NCT07277179
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 20, 2023
- Primary completion
- Jul 5, 2024
- Completion date
- May 16, 2025
- First posted
- Dec 11, 2025
- Last posted
- Dec 11, 2025
- Enrollment
- 113
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BiocadLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.